Gene Network Sciences wins new US patent
REFS platform, enables rapid extraction of actionable, patient-specific knowledge directly from experimental and clinical data
Gene Network Sciences, a biotechnology company, has received a US patent that covers the company's core model learning and simulation platform, REFS.
Gene Network Sciences (GNS) has deployed the Reverse Engineering and Forward Simulation (REFS) platform in several collaborations with pharmaceutical and biotechnology companies and academic and clinical institutions in diseases areas such as oncology, rheumatoid arthritis, cardiovascular and metabolic disease, and Alzheimer's disease.
The REFS platform, which is run on supercomputers, enables the rapid extraction of actionable, patient-specific knowledge directly from experimental and clinical data, the company said.
GNS has several other pending patent applications addressing the REFS platform and its use in areas of application in biological systems and areas outside of biology such as quantitative finance, online advertising, and natural resource exploration, as well as applications covering drug targets, biomarkers, and diagnostic markers discovered using the REFS platform.
Tom Neyarapally, senior vice president of corporate development at GNS, said: We have now extended our patent portfolio beyond our previous issued patents covering an ultra-efficient language to model known biology and the simulation of known pathways, to the fully data-driven inference and simulation of novel biology. GNS now has broad intellectual property coverage across our modeling and simulation activities.
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Regulatory Affairs Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.